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Products from the hydrolysis of phosphatidylinositol 4,5-bisphosphate (IP3) can increase and/or potentiate 
cAMP accumulation i a variety of cells. Antibody to surface immunoglobulins activates IP 3 hydrolysis 
in B-lymphocytes. In this study we have examined whether anti-Ig also stimulated and/or potentiated in- 
creases in the cAMP levels of splenocytes from athymic nude mice. Furthermore, since TPA potentiates 
anti-Ig-induced DNA synthesis and cAMP modulates DNA synthesis, the effects of TPA on any anti-Ig- 
induced changes in cAMP were also studied. Antibody (25 ltg/ml) stimulated a rapid rise in cAMP which 
increased from 250 fmol/106 cells to 400 fmol/106 cells within 1 min and then subsided to 310 fmol/106 cells 
by 10 rain. TPA (96 riM) suppressed the anti-Ig-induced cAMP accumulation at I min by 60%, but poten- 
tiated the forskolin (114 pM)-induced rise by 151%. Two other activators of protein kinase C, dioctanoylgly- 
cerol (5 pM), and anti-Ig (25 pg/ml), also potentiated the forskolin response by 198% and 52%, respectively. 
These results suggest hat modulation of the adenylate cyclase system by anti-Ig may act in concert with 
cytokines and/or prostaglandins secreted by other lymphoid cells to define the state of proliferation or diffe- 
rentiation in B-cells. 
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1. INTRODUCTION 
Recently we reported that TPA potentiated anti- 
Ig-induced DNA synthesis in B-lymphocytes [1]. 
Two receptor-coupled effector systems whose 
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products modulate DNA synthesis are the ade- 
nylate cyclase [2-4] and inositol phospholipid- 
dependent phospholipase C-coupled systems [5]. 
Adenylate cyclase-coupled systems generate 
cAMP, whereas phospholipase C-coupled systems 
produce IP3 and diacylglycerol [6,7]. The products 
from each effector system can modulate the cou- 
pling or activity of the other system. For example, 
permeable analogs of cAMP or activators of 
adenylate cyclase can inhibit agonist-induced 
arachidonic acid release, and inositol phospholipid 
metabolism [8]. Alternatively, activation of 
phospholipase C modulates the adenylate cyclase 
system in different ways: production of IP3, and 
mobilization of Ca 2+ raise cAMP levels [9-12], 
whereas activation of protein kinase C can either 
enhance [13-16] or inhibit [17-20] agonist-induced 
increases in cAMP. 
Since cross-talk between the phospholipase C
and adenylate cyclase signaling systems is highly 
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cell type specific and anti-Ig activates the 
phospholipase C signaling system, we studied 
whether anti-Ig induced changes in the cAMP 
levels. Furthermore, since cAMP modulates DNA 
synthesis and TPA potentiates anti-lg-induced 
DNA synthesis, we investigated whether TPA 
modulates any anti-Ig-induced cAMP accumula- 
tion in splenocytes from athymic nude mice. 
Splenocytes from young athymic nu/nu mice (< 12 
weeks old) were chosen because they contain fewer 
Thy-1 + ceils than their nu /+ counterparts, do not 
express mature T-cell functions uch as production 
of IL-2, cytotoxic T-lymphocyte responses or 
mitogenic responses to Con A, and therefore do 
not interact with or modulate B-lymphocyte 
responses [21]. We report here that anti-Ig induces 
an increase in cAMP and that TPA suppresses this 
stimulation while it enhances the forskolin-induced 
increase. 
2. MATERIALS AND METHODS 
Dupont-New England Nuclear supplied the lzsI- 
SCAMP. BSA, anti-Ig, IBMX, TPA, forskolin, 
ficol-paque, Hepes, PEG-8000, cAMP, c-globulin, 
triethylamine, acetic anhydride and PGE1 were 
purchased from Sigma (St. Louis, MO). Dr Janice 
Douglas, Department of Medicine CWRU, kindly 
provided the antibody to SCAMP. 
Athymic nude mice, 49-51 days old, were ob- 
tained from Charles River Labs. The spleens were 
isolated and single cell suspensions prepared in a 
balanced salt solution containing (in raM) 120 
NaCI, 25 Hepes (pH 7.4), 5 KCI, 1 MgCl2, 1 CaClz 
and 1 mg/ml BSA (BSS/BSA) by pressing the 
spleens through a 100 mesh stainless teel screen. 
The cells were washed 3 x by centrifugation, and 
the red blood cells were separated on a discon- 
tinuous ficol-paque gradient (d= 1.09) by cen- 
trifugation at 800 x g for 30 rain. The cells were 
washed 3 x in BSS/BSA, resuspended at 1.25 x 
l0 6 cells/ml and stored at 0-4°C in BSS/BSA with 
500/~M IBMX. Experiments performed without 
IBMX showed no qualitative differences. 
cAMP was extracted in the following manner. 
The cells were sedimented for 30 s in an Eppendorf 
model 5412 microcentrifuge, chilled on ice for 30 
s, the supernatant was aspirated off, and ice cold 
0.1 N HC1 was added to the pellet. The solutions 
were then stored overnight at 0-4°C before freez- 
ing at - 70°C. The solutions were then assayed us- 
ing a radioimmunoassay [22]. 
3. RESULTS AND DISCUSSION 
A few recent reports have indicated that ac- 
tivating the PIP2 cascade increases and/or poten- 
tiates cAMP accumulation in various cell types 
such as rat pinealocytes, vascular smooth muscle 
cells, and neutrophils [9-12]. Since cross linking 
surface immunoglobulins on B-lymphocytes with 
anti-Ig activates PIP2 hydrolysis [23,24], it was in- 
teresting to investigate whether anti-Ig also 
stimulated and/or potentiated increased the levels 
of cAMP. Fig. 1 shows the results of experiments 
which investigated the effects of anti-Ig on cAMP 
levels in B-lymphocytes. Addition of anti-Ig 
stimulates a very rapid rise in the concentration of
cAMP, which peaks within 2 min and then sub- 
sides to levels above the initial values. This rise in 
cAMP concentration i creased with larger doses of 
anti-Ig beginning with 5 /zg/ml and continuing 
through 25/A/ml (not shown). 
Many investigators have reported that cAMP 
modulates DNA synthesis and the cell type in B- 
lymphocytes [2,4,20], while others have reported 
that TPA potentiates anti-Ig-induced DNA syn- 
thesis [1,25]. Thus, the potentiation by TPA of the 
anti-Ig-induced DNA synthesis may result from a 
modulation of the anti-Ig-induced increase in 
cAMP. The experiments whose results are ex- 
hibited in fig. 1 also examined the effects of TPA 
on the anti-Ig-induced changes in cAMP. 
Although the kinetics remained unchanged, TPA 
decreased the anti-Ig-induced cAMP accumula- 
tion. Pretreating the ceils with TPA for 3 rain 
reduced the anti-Ig-induced increase in cAMP at 1 
min by more than 60%. 
The effect of TPA on the anti-lg-induced 
changes in cAMP may result from a modification 
of the phospholipase C- or adenylate cyclase- 
coupled effector systems. Several reports indicate 
that TPA inhibits the PIPz cascade and Ca z+ 
mobilization in many systems including lym- 
phocytes [26,27], can phosphorylate he adenylate 
cyclase of frog erythrocytes [16] and modify the 
guanine nucleotide-binding protein Ni of human 
platelets [28]. Studying the effects of TPA on 
forskolin-induced increases in cAMP can aid in 
elucidating the mechanism by which TPA 
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Fig.1. Temporal dependence of the anti-lg-induced 
cAMP accumulation: modulation by TPA. Cells (1.25 
X 10 6 cells/ml) were incubated at 37°C for 10 min with 
IBMX prior to an incubation for the indicated time with 
25/~g/ml anti-IgM in the presence of vehicle (o) or 96 
nM TPA (e) added 3 min prior to antibody. Values are 
the means _+ SE of a single representative experiment 
performed in triplicate. 
decreases the anti-Ig-induced increase in cAMP. 
Since forskolin interacts with adenylate cyclase, 
any interaction of TPA with adenylate cyclase 
should express itself by modifying the forskolin- 
induced increase in cAMP [29]. Figs 2 and 3 show 
the results of experiments that studied whether 
modification of adenylate cyclase by TPA could 
account for the observed ecrease discussed above. 
In splenocytes from athymic nude mice, TPA 
potentiated the forskolin-induced increase in 
cAMP. This potentiation i creased with forskolin 
concentration. TPA-treated cells, in the presence 
of 500/~M IBMX, increased the forskolin-induced 
cAMP increase by 60%, whereas treating the cells 
with 114/~M forskolin following exposure to TPA 
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Fig.2. Potentiation of the forskolin-induced cAMP ac- 
cumulation by TPA. Cells were treated as in fig. 1 except 
that a 10 min incubation with the indicated amount of 
forskolin replaced anti-lgM and 48 nM TPA was used. 
Values are the means + SD of a single representative ex- 
periment performed in triplicate. 
increased the cAMP concentration 128% com- 
pared with forskolin alone (fig.2). Fig.3 shows that 
the magnitude of the TPA-induced potentiation 
also increased with the duration of forskolin ex- 
posure. Thus, while TPA certainly modifies the 
adenylate cyclase system, this modification cannot 
explain the TPA-induced suppression of the anti- 
Ig-induced increase in cAMP. 
TPA activates protein kinase C [6], and this ac- 
tivation may explain the observed potentiation of 
the forskolin-induced response. 
This implies that other activators of protein 
kinase C, such as diacylglycerols or agonists which 
generate diacylglycerol, should also potentiate the 
forskolin response. Experiments that compared 
the effects of TPA with those of diC8 and anti-Ig 
on forskolin-induced cAMP accumulation are 
depicted in fig.4. A 3 min preincubation with 
either 5/zM diC8 or 25/~g/ml anti-Ig potentiated 
the forskolin response. 
There are no published experiments on the ef- 
fects of anti-Ig on B-cell cAMP levels. However, 
Cambier et al. [30] reported under 'data not 
shown' that monoclonal antibodies against im- 
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Fig.3. Temporal response of the forskolin-induced 
cAMP accumulation: modulation by TPA. Cells were 
treated as in fig.2 and incubated in 10#M forskolin for 
the indicated time in the presence of vehicle (©) or 48 
nM TPA (e). Values are the means +_ SD of a single 
representative experiment performed in triplicate. 
munoglobulins had no effect on the cAMP levels 
in highly purified small B-lymphocytes, whereas 
Muraguchi et al. [29] speculated from 'data not 
shown' that stimulation with anti-IgM induced a 
steady increase in adenylate cyclase activity in 
highly purified small B-cells within the first 24 h. 
The results reported in this paper support he com- 
ment made by Muraguchi and are consistent with 
reports that other activators of PIP2 hydrolysis 
also induce increases in cAMP levels and/or poten- 
tiate agonist-induced cAMP accumulation i other 
cells [9-12]. 
The experiments tudying the mechanism by 
which TPA suppresses the anti-Ig-induced increase 
in cAMP do not examine events upstream of 
adenylate cyclase. Thus, the suppression might 
result from an alteration of the adenylate cyclase- 
coupled G proteins, a modification in the antigen- 
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Fig.4. Potentiation of forskolin-induced cAMP ac- 
cumulation by activators of protein kinase C or 
generators of diacylglycerols. Cells were treated as in 
fig.2, using 114 #M forskolin and the agents indicated in 
the figure. 
receptor interaction, or an alteration in the 
mechanism that mediates the cross-talk between 
the phospholipase C- and adenylate cyclase- 
coupled effector systems. Alternatively, the anti- 
Ig-induced rise in cAMP may indirectly result from 
the hydrolysis of PIP2, and the TPA-induced sup- 
pression might reflect inhibition of that hydrolysis. 
In conclusion, anti-Ig induces a biphasic in- 
crease in the levels of cAMP. Whether this increase 
results from a direct activation of adenylate 
cyclase, an indirect activation by secondary or ter- 
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tiary messengers generated by PIP2 hydrolysis, or 
by inhibition of a cAMP-dependent phosphodi- 
esterase remains unclear. In addition, TPA sup- 
presses the anti-Ig-induced and potentiates the 
forskolin-induced increase in cAMP. The observa- 
tions that TPA, diCs, or anti-Ig can potentiate the 
forskolin-induced increase in cAMP implies that 
generators of diacylglycerols, i.e. antigen, can 
prime the adenylate cyclase system in B-cells. Since 
changes in the intracellular cyclic nucleotide con- 
centration can modulate B-cell proliferation and 
differentiation [4,30-32], this priming may act in 
concert with cytokines and/or prostaglandins 
secreted by macrophages or T-cells to define the 
state of proliferation or differentiation i  B-cells. 
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